1219000-72-2

Upstream product

• 461432-26-8 dapagliflozin 

Downstream Products

• 1219001-05-4 (4-{(2S,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxytetrahydro-pyran-2-ylmethylsulfanyl}-phenyl)-acetic acid methyl ester 
• 1219001-31-6 (2S,3S,4R,5R,6S)-2-(5-amino-2-fluoro-phenylsulfanylmethyl)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol 
• 1219001-37-2 3-{(2S,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethylsulfanyl}-4-fluoro-benzoic acid methyl ester 
• 1290630-12-4 (3S,4R,5S,6S)-3,4,5-tris-benzyloxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-tetrahydro-pyran-2-ol 
• 1290630-14-6 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol 
• 1290630-13-5 (3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-hydroxymethyl-tetrahydro-pyran-2,3,4,5-tetraol 
• 1290630-18-0 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-trifluoromethanesulfonyloxy-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-ylester. 
• 1290630-19-1 (5S,6S,7R,8S)-5-(4-chloro-3-(4-(pyrrolidin-1-yl)benzyl)phenyl)-4-oxaspiro[2.5]octane-6,7,8-triyl triacetate 
• 1290630-20-4 (5S,6R,7R,8S)-5-[4-chloro-3-(4-pyrrolidin-1-yl-benzyl)-phenyl]-4-oxa-spiro[2.5]octane-6,7,8-triol 
• 1290630-23-7 acetic acid (5S,6S,7R,8S)-7,8-diacetoxy-5-[4-chloro-3-(4-hydroxy-3-nitro-benzyl)-phenyl]-4-oxa-spiro[2.5]oct-6-yl ester 
• 1290630-24-8 {4-[2-chloro-5-((5S,6S,7R,8S)-6,7,8-triacetoxy-4-oxa-spiro[2.5]oct-5-yl)-benzyl]-2-nitro-phenoxy}-acetic acid ethyl ester 
• 1064255-47-5 (2S,3R,4R,5S)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylene-tetrahydro-pyran-3,4,5-triol 
• 1290629-68-3 (2S,3S,4R,5S)-3,4,5-tris-benzyloxy-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylene-tetrahydro-pyran 
• 1290629-69-4 (5S,6S,7R,8S)-6,7,8-tris-benzyloxy-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-4-oxa-spiro[2.5]octane 

Relevant academic research and scientific papers

Copper-Catalyzed Difluoromethylation of Alkyl Iodides Enabled by Aryl Radical Activation of Carbon–Iodine Bonds

The engagement of unactivated alkyl halides in copper-catalyzed cross-coupling reactions has been historically challenging, due to their low reduction potential and the slow oxidative addition of copper(I) catalysts. In this work, we report a novel strategy that leverages the halogen abstraction ability of aryl radicals, thereby engaging a diverse range of alkyl iodides in copper-catalyzed Negishi-type cross-coupling reactions at room temperature. Specifically, aryl radicals generated via copper catalysis efficiently initiate the cleavage of the carbon–iodide bonds of alkyl iodides. The alkyl radicals thus generated enter the copper catalytic cycles to couple with a difluoromethyl zinc reagent, thus furnishing the alkyl difluoromethane products. This unprecedented Negishi-type difluoromethylation approach has been applied to the late-stage modification of densely functionalized pharmaceutical agents and natural products.

GLYCOSIDE DERIVATIVE AND USES THEREOF

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

GLUCOSIDE DERIVATIVES AND USES THEREOF

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, and to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.

GLYCOSIDE DERIVATIVE AND USES THEREOF

This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.

GLYCOSIDE DERIVATIVES AND USES THEREOF

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of, interalia, metabolic disorders.